Base de dados : MEDLINE
Pesquisa : D03.383.129.308.436.750 [Categoria DeCS]
Referências encontradas : 836 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 84 ir para página                         

  1 / 836 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25775096
[Au] Autor:Dahlström M; Sjögren M; Jonsson PR; Göransson U; Lindh L; Arnebrant T; Pinori E; Elwing H; Berglin M
[Ad] Endereço:a Unit for Chemistry, Materials and Surfaces , SP Technical Research Institute of Sweden , Borås , Sweden.
[Ti] Título:Affinity states of biocides determine bioavailability and release rates in marine paints.
[So] Source:Biofouling;31(2):201-10, 2015.
[Is] ISSN:1029-2454
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A challenge for the next generation marine antifouling (AF) paints is to deliver minimum amounts of biocides to the environment. The candidate AF compound medetomidine is here shown to be released at very low concentrations, ie ng ml(-1) day(-1). Moreover, the release rate of medetomidine differs substantially depending on the formulation of the paint, while inhibition of barnacle settlement is independent of release to the ambient water, ie the paint with the lowest release rate was the most effective in impeding barnacle colonisation. This highlights the critical role of chemical interactions between biocide, paint carrier and the solid/aqueous interface for release rate and AF performance. The results are discussed in the light of differential affinity states of the biocide, predicting AF activity in terms of a high surface affinity and preserved bioavailability. This may offer a general framework for the design of low-release paint systems using biocides for protection against biofouling on marine surfaces.
[Mh] Termos MeSH primário: Incrustação Biológica/prevenção & controle
Desinfetantes/química
Medetomidina/química
Pintura
Thoracica/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Disponibilidade Biológica
Estrutura Molecular
Thoracica/fisiologia
Tolazolina/química
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Disinfectants); CHH9H12AQ3 (Tolazoline); MR15E85MQM (Medetomidine)
[Em] Mês de entrada:1507
[Cu] Atualização por classe:150317
[Lr] Data última revisão:
150317
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150317
[St] Status:MEDLINE
[do] DOI:10.1080/08927014.2015.1012639


  2 / 836 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25510072
[Au] Autor:Vakrilova L; Radulova P; Hitrova S; Slancheva B
[Ti] Título:[Pulmonary hypertension of the newborn--recent advances in the management and treatment].
[So] Source:Akush Ginekol (Sofiia);53(4):50-8, 2014.
[Is] ISSN:0324-0959
[Cp] País de publicação:Bulgaria
[La] Idioma:bul
[Ab] Resumo:Pulmonary hypertension of the newborn is a clinical syndrome with diverse etiology in which the transition from fetal circulation with high pulmonary vascular resistance to postnatal circulation with low pulmonary vascular resistance failed. The persistence of high pulmonary vascular pressure leads to right-left shunts and marked cyanosis. Despite of the advances in neonatology, the treatment of some forms of PPHN is often difficult and mortality rate remains high. In infants with PPHN appropriate interventions are critical to reverse hypoxemia, improve pulmonary and systemic perfusion and preserve end-organ function. Our understanding for management of PPHN has evaluated over decades. This review summarizes the current strategies for treatment of pulmonary hypertension of the newborn: general care, cardiovascular support, the advantages and limitations of different ventilatory strategies, oxygen therapy, extracorporal membrane oxygenation, and the evidence-based inhaled nitric oxide therapy. The balance between pulmonary vasoconstrictor and vasodilator mediators plays an important role for pulmonary vascular resistance. Recent studies are designed to develop evidence-based therapies for regulation of pulmonary vascular tone, safe medications for selective pulmonary vasodilatation effective for treatment of PPHN and other forms of pulmonary hypertension in the neonatal intensive care unit.
[Mh] Termos MeSH primário: Hipertensão Pulmonar/terapia
Doenças do Recém-Nascido/terapia
[Mh] Termos MeSH secundário: Antioxidantes/uso terapêutico
Broncodilatadores/uso terapêutico
Oxigenação por Membrana Extracorpórea/métodos
Seres Humanos
Recém-Nascido
Pulmão/efeitos dos fármacos
Óxido Nítrico/uso terapêutico
Oxigenoterapia/métodos
Tolazolina/uso terapêutico
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antioxidants); 0 (Bronchodilator Agents); 0 (Vasodilator Agents); 31C4KY9ESH (Nitric Oxide); CHH9H12AQ3 (Tolazoline)
[Em] Mês de entrada:1501
[Cu] Atualização por classe:150320
[Lr] Data última revisão:
150320
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141217
[St] Status:MEDLINE


  3 / 836 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24807358
[Au] Autor:Wolfe LL; Fisher MC; Davis TR; Miller MW
[Ad] Endereço:1 Colorado Division of Parks and Wildlife, Wildlife Research Center, 317 West Prospect Road, Fort Collins, Colorado 80526-2097, USA.
[Ti] Título:Efficacy of a low-dosage combination of butorphanol, azaperone, and medetomidine (BAM) to immobilize Rocky Mountain elk.
[So] Source:J Wildl Dis;50(3):676-80, 2014 Jul.
[Is] ISSN:1943-3700
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We compared dosages of a combination of sedatives, which included butorphanol tartrate, azaperone tartrate, and medetomidine HCl (BAM) in captive adult Rocky Mountain elk (Cervus elaphus nelsoni). All three BAM dosages (low, medium, and high) effectively immobilized elk and produced an adequate level of sedation in all subjects. Induction times were similar among the three groups (mean ± SD: low=6.9 ± 1.1 min; medium=6.3 ± 0.9 min; high=4.7 ± 1.3 min). Most elk became hypoxemic regardless of BAM dosage, but hypoxemia tended to be most severe in the high-BAM group; regardless of BAM dosage, oxygen supplementation improved the percentage of oxygen saturation and stabilized the vital rates. Recovery after administration of antagonists (3 mg atipamezole/mg medetomidine and 2 mg/kg tolazoline) was comparable among groups (range of means=9 ± 1.5-11.7 ± 1 min). Based on the findings from clinical trials and field data from free-ranging elk immobilizations, we recommend low-dose BAM (2 mL dose; equivalent to 46 mg butorphanol, 30 mg azaperone, and 18 mg medetomidine) and supplemental oxygen for adult elk; immobilization should be antagonized using 3-5 mg atipamezole/mg medetomidine and 2 mg/kg tolazoline, with tolazoline injected about 5-10 min before atipamezole to smooth out recovery.
[Mh] Termos MeSH primário: Azaperona/farmacologia
Butorfanol/farmacologia
Cervos/fisiologia
Imobilização/veterinária
Medetomidina/farmacologia
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos alfa 2/administração & dosagem
Antagonistas de Receptores Adrenérgicos alfa 2/farmacologia
Antagonistas Adrenérgicos alfa/administração & dosagem
Antagonistas Adrenérgicos alfa/farmacologia
Analgésicos Opioides/administração & dosagem
Analgésicos Opioides/farmacologia
Animais
Azaperona/administração & dosagem
Butorfanol/administração & dosagem
Relação Dose-Resposta a Droga
Combinação de Medicamentos
Feminino
Hipnóticos e Sedativos/administração & dosagem
Hipnóticos e Sedativos/farmacologia
Imidazóis/administração & dosagem
Imidazóis/farmacologia
Imobilização/métodos
Masculino
Medetomidina/administração & dosagem
Tolazolina/administração & dosagem
Tolazolina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic alpha-2 Receptor Antagonists); 0 (Adrenergic alpha-Antagonists); 0 (Analgesics, Opioid); 0 (Drug Combinations); 0 (Hypnotics and Sedatives); 0 (Imidazoles); 03N9U5JAF6 (atipamezole); 19BV78AK7W (Azaperone); CHH9H12AQ3 (Tolazoline); MR15E85MQM (Medetomidine); QV897JC36D (Butorphanol)
[Em] Mês de entrada:1503
[Cu] Atualização por classe:140704
[Lr] Data última revisão:
140704
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140509
[St] Status:MEDLINE
[do] DOI:10.7589/2014-02-026


  4 / 836 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24134603
[Au] Autor:Knych HK; Stanley SD
[Ad] Endereço:K. L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, CA, USA; Department of Veterinary Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA, USA.
[Ti] Título:Effects of three antagonists on selected pharmacodynamic effects of sublingually administered detomidine in the horse.
[So] Source:Vet Anaesth Analg;41(1):36-47, 2014 Jan.
[Is] ISSN:1467-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To describe the effects of alpha2 -adrenergic receptor antagonists on the pharmacodynamics of sublingual (SL) detomidine in the horse. STUDY DESIGN: Randomized crossover design. ANIMALS: Nine healthy adult horses with an average age of 7.6 ± 6.5 years. METHODS: Four treatment groups were studied: 1) 0.04 mg kg(-1) detomidine SL; 2) 0.04 mg kg(-1) detomidine SL followed 1 hour later by 0.075 mg kg(-1) yohimbine intravenously (IV); 3) 0.04 mg kg(-1) detomidine SL followed 1 hour later by 4 mg kg(-1) tolazoline IV; and 4) 0.04 mg kg(-1) detomidine SL followed 1 hour later by 0.12 mg kg(-1) atipamezole IV. Each horse received all treatments with a minimum of 1 week between treatments. Blood samples were obtained and plasma analyzed for yohimbine, atipamezole and tolazoline concentrations by liquid chromatography-mass spectrometry. Behavioral effects, heart rate and rhythm, glucose, packed cell volume (PCV) and plasma proteins were monitored. RESULTS: Chin-to-ground distance increased following administration of the antagonists, however, this effect was transient, with a return to pre-reversal values as early as 1 hour. Detomidine induced bradycardia and increased incidence of atrioventricular blocks were either transiently or incompletely antagonized by all antagonists. PCV and glucose concentrations increased with tolazoline administration, and atipamezole subjectively increased urination frequency but not volume. CONCLUSIONS AND CLINICAL RELEVANCE: At the doses administered in this study, the alpha2 -adrenergic antagonistic effects of tolazoline, yohimbine and atipamezole on cardiac and behavioral effects elicited by SL administration of detomidine are transient and incomplete.
[Mh] Termos MeSH primário: Cavalos/sangue
Imidazóis/farmacologia
Imidazóis/farmacocinética
Tolazolina/farmacologia
Ioimbina/farmacologia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos alfa/administração & dosagem
Antagonistas Adrenérgicos alfa/sangue
Antagonistas Adrenérgicos alfa/farmacocinética
Antagonistas Adrenérgicos alfa/farmacologia
Animais
Estudos Cross-Over
Interações Medicamentosas
Feminino
Imidazóis/administração & dosagem
Imidazóis/sangue
Masculino
Tolazolina/administração & dosagem
Tolazolina/sangue
Tolazolina/farmacocinética
Ioimbina/administração & dosagem
Ioimbina/sangue
Ioimbina/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 0 (Imidazoles); 03N9U5JAF6 (atipamezole); 2Y49VWD90Q (Yohimbine); 7N8K34P2XH (detomidine); CHH9H12AQ3 (Tolazoline)
[Em] Mês de entrada:1408
[Cu] Atualização por classe:170408
[Lr] Data última revisão:
170408
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131019
[St] Status:MEDLINE
[do] DOI:10.1111/vaa.12081


  5 / 836 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23996466
[Au] Autor:Carter SG; Zhu Z; Varadi G; Veves A; Riviere JE
[Ad] Endereço:BioChemics, Inc, Danvers, Massachusetts, 01923.
[Ti] Título:Vasomodulation influences on the transdermal delivery of Ibuprofen.
[So] Source:J Pharm Sci;102(11):4072-8, 2013 Nov.
[Is] ISSN:1520-6017
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The purpose of the study was to evaluate the effect of adding peripheral vasodilators, tolazoline, or papaverine, to transdermal drug delivery vehicles with the goal of improving the tissue bioavailability of transdermally delivered ibuprofen. Ibuprofen (150 mg) formulations with several concentrations of two different vasodilators and/or a penetration enhancer (PE) complex were topically applied to rabbits. Plasma levels of ibuprofen were determined by a validated high-performance liquid chromatography method and evaluated at 0, 0.5, 1, 2, and 3 h. The PE complex enhanced the plasma ibuprofen level approximately sevenfold versus control, and tolazoline (0.005%) added to the PE complex increased the plasma levels of ibuprofen approximately another twofold compared with the PE. Higher concentrations of tolazoline paradoxically did not exhibit vasodilator enhancement to ibuprofen delivery. Papaverine was tested in the same manner. In this set of experiments, PE increased the plasma ibuprofen 3.7-fold versus control, and addition of papaverine (0.0005%) increased plasma ibuprofen an additional 3.3-fold compared with the PE formulation. Transdermal formulations of ibuprofen containing low concentrations of tolazoline or papaverine increased plasma ibuprofen levels in the presence of passive PE components.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/administração & dosagem
Ibuprofeno/administração & dosagem
Papaverina/farmacologia
Absorção Cutânea/efeitos dos fármacos
Tolazolina/farmacologia
Vasodilatadores/farmacologia
[Mh] Termos MeSH secundário: Administração Cutânea
Animais
Anti-Inflamatórios não Esteroides/sangue
Anti-Inflamatórios não Esteroides/farmacocinética
Ibuprofeno/sangue
Ibuprofeno/farmacocinética
Permeabilidade/efeitos dos fármacos
Coelhos
Pele/efeitos dos fármacos
Pele/metabolismo
Tolazolina/administração & dosagem
Vasodilatadores/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Vasodilator Agents); CHH9H12AQ3 (Tolazoline); DAA13NKG2Q (Papaverine); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:1405
[Cu] Atualização por classe:131014
[Lr] Data última revisão:
131014
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130903
[St] Status:MEDLINE
[do] DOI:10.1002/jps.23719


  6 / 836 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23438114
[Au] Autor:Yokota S; Hikasa Y; Shimura I; Kusunose S
[Ad] Endereço:Department of Veterinary Internal Medicine, Faculty of Agriculture, Tottori University, Koyama-Minami 4-101, Tottori 680-8553, Japan.
[Ti] Título:Effects of imidazoline and nonimidazoline alpha-adrenergic agents, including xylazine, medetomidine, yohimbine, tolazoline, and atipamezole, on aggregation of bovine and equine platelets.
[So] Source:Am J Vet Res;74(3):395-402, 2013 Mar.
[Is] ISSN:1943-5681
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To investigate effects of various imidazoline and nonimidazoline α-adrenergic agents on aggregation and antiaggregation of bovine and equine platelets. SAMPLE: Blood samples obtained from 8 healthy adult cattle and 16 healthy adult Thoroughbreds. PROCEDURES: Aggregation and antiaggregation effects of various imidazoline and nonimidazoline α-adrenergic agents on bovine and equine platelets were determined via a turbidimetric method. Collagen and ADP were used to initiate aggregation. RESULTS: Adrenaline, noradrenaline, or α-adrenoceptor agents alone did not induce changes in aggregation of bovine or equine platelets or potentiate ADP- or collagen-induced platelet aggregation. Adrenaline and the α(2)-adrenoceptor agonist clonidine had an inhibitory effect on ADP- and collagen-induced aggregation of bovine platelets. The α(2)-adrenoceptor antagonists phentolamine and yohimbine also inhibited collagen-induced aggregation of bovine platelets. Noradrenaline, other α-adrenoceptor agonists (xylazine, oxymetazoline, and medetomidine), and α-adrenoceptor antagonists (atipamezole, idazoxan, tolazoline, and prazosin) were less effective or completely ineffective in inhibiting ADP- and collagen-induced aggregation of bovine platelets. The imidazoline α(2)-adrenoceptor agonist oxymetazoline submaximally inhibited collagen-induced aggregation of equine platelets, and the α(2)-adrenoceptor antagonist idazoxan, along with phentolamine and yohimbine, also inhibited collagen-induced aggregation of equine platelets. The imidazoline compound antazoline inhibited both ADP- and collagen-induced aggregation of equine platelets. CONCLUSIONS AND CLINICAL RELEVANCE: Several drugs had effects on aggregation of platelets of cattle and horses, and effective doses of ADP and collagen also differed between species. The α(2)-adrenoceptor agonists (xylazine and medetomidine) and antagonists (tolazoline and atipamezole) may be used by bovine and equine practitioners without concern for adverse effects on platelet function and hemostasis.
[Mh] Termos MeSH primário: Adrenérgicos/farmacologia
Bovinos/sangue
Cavalos/sangue
Imidazolinas/farmacologia
Agregação Plaquetária/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Feminino
Imidazóis/farmacologia
Concentração Inibidora 50
Masculino
Medetomidina/farmacologia
Tolazolina/farmacologia
Xilazina/farmacologia
Ioimbina/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic Agents); 0 (Imidazoles); 0 (Imidazolines); 03N9U5JAF6 (atipamezole); 2KFG9TP5V8 (Xylazine); 2Y49VWD90Q (Yohimbine); CHH9H12AQ3 (Tolazoline); MR15E85MQM (Medetomidine)
[Em] Mês de entrada:1309
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130227
[St] Status:MEDLINE
[do] DOI:10.2460/ajvr.74.3.395


  7 / 836 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23321455
[Au] Autor:Casbeer HC; Knych HK
[Ad] Endereço:K.L. Maddy Equine Analytical Chemistry Laboratory, School of Veterinary Medicine, University of California, Davis, USA.
[Ti] Título:Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses.
[So] Source:Vet J;196(3):504-9, 2013 Jun.
[Is] ISSN:1532-2971
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Tolazoline is an α2-adrenergic receptor antagonist, used in veterinary medicine to antagonize the central nervous system depressant and cardiovascular effects of α2 receptor agonists. The pharmacokinetics and pharmacodynamic effects of tolazoline when administered subsequent to detomidine in the horse were recently reported, although the reversal of the sedative and cardiovascular effects following detomidine may not be complete. The current study therefore investigated the pharmacokinetics and pharmacodynamic effects of tolazoline when administered as a sole agent. Nine healthy adult horses were administered tolazoline (4mg/kgIV) and blood samples were collected at time 0 (prior to drug administration) and at various times up to 72h post drug administration. Plasma samples were analyzed using liquid chromatography-mass spectrometry and resulting data analyzed using compartmental analysis. Systemic clearance, steady state volume of distribution and terminal elimination half-life were 0.820±0.182L/h/kg, 1.68±0.379L/kg and 2.69±0.212h, respectively. Tolazoline administration had no effect on chin to ground distance, but the heart rate decreased (relative to baseline) and the percentage of atrial-ventricular block increased in all horses within 2min of administration. Packed cell volume and glucose concentrations were also increased throughout the sampling period. While not commonly used as a sole agent, caution is indicated whenever tolazoline is administered since the effects may be unpredictable.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos alfa/farmacologia
Antagonistas Adrenérgicos alfa/farmacocinética
Cavalos/sangue
Tolazolina/farmacologia
Tolazolina/farmacocinética
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos alfa/administração & dosagem
Antagonistas Adrenérgicos alfa/sangue
Animais
Área Sob a Curva
Proteínas Sanguíneas
Feminino
Meia-Vida
Frequência Cardíaca
Injeções Intravenosas
Masculino
Tolazolina/administração & dosagem
Tolazolina/sangue
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 0 (Blood Proteins); CHH9H12AQ3 (Tolazoline)
[Em] Mês de entrada:1312
[Cu] Atualização por classe:130619
[Lr] Data última revisão:
130619
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130117
[St] Status:MEDLINE


  8 / 836 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:23097963
[Au] Autor:Islami H; Veseli A; Behluli E; Morina N
[Ad] Endereço:Department of Pharmacology, Faculty of Medicine, University of Prishtina. Clinical Centre, Prishtina, Kosova. islamihilmi@hotmail.com
[Ti] Título:Importance of the adrenergic nerve system in the response of gases in the arterial blood following the provoked bronchospasm.
[So] Source:Med Arch;66(5):292-5, 2012.
[Is] ISSN:0350-199X
[Cp] País de publicação:Bosnia and Herzegovina
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: This work, partial pressure of the respiratory gases in the capillary blood (pH, PaO2, PaCO2) was studied, following the protective action of the beta2-drenergic stimulator-Hexoprenaline and alpha2-adrenergic blocker-Tolazoline in the bronchoconstriction caused by a beta-blocker-Propranolol. MATERIAL AND METHODS: in patients with increased bronchial reactibility. pH, oxygen partial pressure (PaO2), dioxide carbon partial pressure (PaCO2) in the arterial blood, with the assistance of the analyzer IL, following some minutes of sample taking were defined in all patients. As a standard to verify the accuracy of the measurement, ampoule solutions of pH, PaO2 and PaCO2 were utilized (Acidobasel, Berlin). RESULTS AND DISCUSSION: Following the inhalation of the beta-blocker-Propranolol (20 mg/ml-aerosol), there was an evident decrease (p < 0.05) of pO2 and a non-significant increase (p > 0.1) of pCO2. Beta2-adrenergcic stimulator-Hexoprenaline (2 inh x 0.2 mg), shows an protective effect in the decrease of pO2 (p < 0.05) following the bronchoconstriction being provoked by Propranolol. Alpha2-adrenergic blocker-Tolazoline (20 mg/ml-aerosol), has not shown a protective action in the bronchoconstriction caused with propranolol, therefore significant decrease (p < 0.05) of pO2 and a non-significant increase (p > 0.1) of pCO2 appeared. This shows that stimulation of beta2-adrenergic receptor has protective action in changes of the respiratory gases. Meantime, blocker of the alpha2-adrenergic receptor (Tolazoline) has not shown a protective action in changes of the respiratory gases.
[Mh] Termos MeSH primário: Espasmo Brônquico/fisiopatologia
Dióxido de Carbono/sangue
Oxigênio/sangue
Receptores Adrenérgicos/fisiologia
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos alfa/farmacologia
Agonistas de Receptores Adrenérgicos beta 2
Antagonistas Adrenérgicos beta/farmacologia
Adulto
Feminino
Hexoprenalina/farmacologia
Seres Humanos
Masculino
Pressão Parcial
Propranolol/farmacologia
Doença Pulmonar Obstrutiva Crônica/fisiopatologia
Troca Gasosa Pulmonar
Tolazolina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 0 (Adrenergic beta-2 Receptor Agonists); 0 (Adrenergic beta-Antagonists); 0 (Receptors, Adrenergic); 142M471B3J (Carbon Dioxide); 9Y8NXQ24VQ (Propranolol); CHH9H12AQ3 (Tolazoline); G9L6B3W684 (Hexoprenaline); S88TT14065 (Oxygen)
[Em] Mês de entrada:1212
[Cu] Atualização por classe:150901
[Lr] Data última revisão:
150901
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121027
[St] Status:MEDLINE


  9 / 836 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23060515
[Au] Autor:Kreeger TJ; Kellie KA
[Ad] Endereço:Wyoming Game and Fish Department, 2362 Highway 34, Wheatland, Wyoming 82201, USA. tkreeger@wildblue.net
[Ti] Título:Sufentanil citrate immobilization of Alaskan moose calves.
[So] Source:J Wildl Dis;48(4):1088-91, 2012 Oct.
[Is] ISSN:1943-3700
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Free-ranging Alaskan moose calves (Alces alces gigas) were immobilized with 0.12 mg/kg sufentanil (S; n=16), 0.12 mg/kg sufentanil plus 0.27 mg/kg xylazine (SX; n=11), or 0.007 mg/kg carfentanil plus 0.36 mg/kg xylazine (CX; n=13). Immobilants were antagonized with 1.2 mg/kg naltrexone (S) or 1.2 mg/kg naltrexone plus 2.4 mg/kg tolazoline (SX, CX). There were no differences in induction (P ≥ 0.29) or processing (P ≥ 0.44) times between groups. Moose given either S or SX had significantly shorter recovery times than moose given CX (P=0.001) and recovery times from S were shorter than from SX (P=0.02). Oxygen saturation values for all groups averaged 85 ± 8%, but were significantly higher (P=0.048) for CX (89 ± 7%) than for S (82 ± 8%). Based on these data, sufentanil at 0.1 mg/kg or sufentanil at 0.1 mg/kg plus xylazine at 0.25 mg/kg could provide effective remote immobilization for Alaskan moose calves and could be substituted for carfentanil or thiafentanil should the need arise.
[Mh] Termos MeSH primário: Cervos/fisiologia
Imobilização/veterinária
Entorpecentes/farmacologia
Sufentanil/farmacologia
[Mh] Termos MeSH secundário: Alaska
Período de Recuperação da Anestesia
Animais
Animais Recém-Nascidos
Animais Selvagens
Relação Dose-Resposta a Droga
Feminino
Fentanila/análogos & derivados
Fentanila/farmacologia
Imobilização/métodos
Masculino
Naltrexona/administração & dosagem
Oxigênio/sangue
Respiração/efeitos dos fármacos
Fatores de Tempo
Tolazolina/administração & dosagem
Xilazina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Narcotics); 2KFG9TP5V8 (Xylazine); 5S6W795CQM (Naltrexone); AFE2YW0IIZ (Sufentanil); CHH9H12AQ3 (Tolazoline); LA9DTA2L8F (carfentanil); S88TT14065 (Oxygen); UF599785JZ (Fentanyl)
[Em] Mês de entrada:1212
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:121013
[St] Status:MEDLINE
[do] DOI:10.7589/2012-04-112


  10 / 836 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:22946377
[Au] Autor:Mortenson JA; Robison JA
[Ad] Endereço:U.S. Department of Agriculture, Veterinary Services, 530 Center Street NE, Suite 335, Salem, Oregon 97301, USA. jack.a.mortenson@usda.gov
[Ti] Título:Tolazoline-induced apnea in mule deer (Odocoileus hemionus).
[So] Source:J Zoo Wildl Med;42(1):105-7, 2011 Mar.
[Is] ISSN:1042-7260
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Eighteen mule deer (Odocoileus hemionus) and six Columbia black-tailed deer (Odocoileus hemionus columbianus) were held in pens and repeatedly anesthetized from April 2004 through June 2005 as part of an external parasite study. Deer were anesthetized using a combination of Telazol and xylazine hydrochloride (HCL) administered intramuscularly. Tolazoline HCL was slowly administered at 4 mg/kg intravenously to reverse the effects of xylazine with good results. For 17 of the 19 mule deer anesthesias in the fall of 2004, a mean dose of 7.3 mg/kg of intravenous tolazoline (range 6.1-8.4 mg/kg) was given by mistake. This paper describes clinical signs of apnea, muscle tensing, and fasciculations immediately following intravenous administration of tolazoline HCL in mule deer (O. hemionus) at 1.5-3 times the recommended dose. Mean dose for black-tailed deer during this time was 8.1 mg/kg (range 5.5-12.4 mg/kg) with no clinical signs as seen in the mule deer. Based on these findings, intravenous tolazoline use in mule deer is recommended at < or = 4 mg/kg.
[Mh] Termos MeSH primário: Antagonistas Adrenérgicos alfa/administração & dosagem
Antagonistas Adrenérgicos alfa/efeitos adversos
Apneia/veterinária
Cervos
Tolazolina/administração & dosagem
Tolazolina/efeitos adversos
[Mh] Termos MeSH secundário: Anestésicos/farmacologia
Animais
Apneia/induzido quimicamente
Relação Dose-Resposta a Droga
Overdose de Drogas/veterinária
Fasciculação/induzido quimicamente
Fasciculação/veterinária
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 0 (Anesthetics); CHH9H12AQ3 (Tolazoline)
[Em] Mês de entrada:1209
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120906
[St] Status:MEDLINE



página 1 de 84 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde